NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Remember Dr. Liau's presentation way back during December 2016 when she stated that about 86% of the trial had at some point received the vaccine and therefore about 14% did not. Her statement may have been based on data collected months prior to December 2016 and implied at the time that 46 of the 99 placebos had not yet crossed over.

However, the JTM publication that was based on the data collected during March 2017 (only 3 months after LL's presentation) stated that about 90% of the trial had received DCVax-L at some point and implied that 10% of the trial or only about 33 patients had not yet crossed over.

Original randomization (2:1 = 220+ 111 placebos)
220 + 66 cross-over placebos = 286 DCvax-L patients = 86,4%

Real randomization (2,3:1 = 232+99 placebos)
232 + 66 cross-over placebos = 298 DCvax-L patients = 90,03%